build, grow and invest in
that put patients first.
Harrow Health, Inc. (NASDAQ: HROW) owns a diversified portfolio of healthcare businesses, including the nation’s leading ophthalmic pharmaceutical compounding business, ImprimisRx®. The company holds large equity positions in Eton Pharmaceuticals (NASDAQ: ETON), Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals, Radley Pharmaceuticals, and Stowe Pharmaceuticals, companies founded as subsidiaries of Harrow.
At Harrow, we focus on pursuing opportunities for drug candidates in underserved markets. We are data driven; and use our access to real-world clinical experience to lower the investment risks of the work we do. We concentrate on the commercial appeal of high-value assets and our objective is to seek to make paradigm-shifting medicines available to patients as soon as possible. We believe our approach to finding high value opportunities and balancing risk with real world experience can deliver exceptional value for all of our stakeholders.
Radley Pharmaceuticals is focused on rare diseases and orphan drug indications, including anti-infective, immuno-oncology, and oncology. Radley’s RAD-100, focused on oncology, will carry out pre-clinical studies with a major Boston-based healthcare organization in the second half of 2019. All Radley drug candidates will purse FDA approval via the 505(b)(2) pathway.
Stowe Pharmaceuticals acquired worldwide rights to Zian™, which is a patented small molecule, which was developed to treat various complex bacterial, fungal, and viral infections, including in the eye and ear within 15 seconds in pre-clinical studies. The drug candidate, STE-006, will pursue FDA approval via the 505(b)(1) pathway and is based on the Zian molecule. The potential addressable U.S. market for STE-006 is estimated to be $2 billion.
Mayfield Pharmaceuticals is focused on the development and commercialization of solutions that address unmet or underserved needs in the women’s health sector. Mayfield’s current candidates will pursue approval for dyspareunia, bacterial vaginosis, and interstitial cystitis, addressable markets that are collectively estimated at roughly $3 billion.
Melt Pharmaceuticals is developing patented non-opioid sublingual sedation/analgesia drug candidates, a multi-billion-dollar market opportunity as alternatives to IV sedation. Melt hopes its product candidates, if approved, will serve the ophthalmology, dental, MRI, and other health care sub-markets. Harrow owns 3.5 million shares of Melt (approximately 44%) and completed a Pre-IND meeting with FDA in January 2019.
Surface Pharmaceuticals is focused on the > $1 billion ocular surface disease and related markets, including chronic, episodic, and refractory dry eye disease, pain and inflammation post ocular surgery, and blepharitis. Harrow owns 3.5 million shares of Surface (roughly 30% equity interest), which completed its Series A financing from Flying L Partners in May 2018.
Eton Pharmaceuticals is focused on drug candidates requiring single PIII trials, bio-equivalence, or literature-based 505(b)(2) NDA filings. Their current portfolio contains eight product candidates with an addressable market of > $4.4 billion. Harrow owns 3.5 million shares of Eton, which completed its IPO in November 2018 (NASDAQ: ETON).
ImprimisRx is the nation’s leading ophthalmology pharmaceutical compounding business, serving thousands of ophthalmologists in all 50 states providing access to novel medications at affordable prices.